Cramer Rosenthal Mcglynn LLC Has $36.83 Million Stake in Masimo Co. (NASDAQ:MASI)

Cramer Rosenthal Mcglynn LLC lifted its stake in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 20.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 222,817 shares of the medical equipment provider's stock after buying an additional 37,800 shares during the period. Masimo comprises about 2.1% of Cramer Rosenthal Mcglynn LLC's holdings, making the stock its 7th largest position. Cramer Rosenthal Mcglynn LLC owned approximately 0.42% of Masimo worth $36,832,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of MASI. Jones Financial Companies Lllp bought a new position in shares of Masimo in the fourth quarter valued at approximately $27,000. UMB Bank n.a. grew its stake in Masimo by 180.9% in the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock valued at $32,000 after purchasing an additional 123 shares during the period. Trust Co. of Vermont purchased a new stake in shares of Masimo during the 4th quarter valued at $33,000. Blue Trust Inc. raised its stake in shares of Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock worth $33,000 after purchasing an additional 71 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Masimo by 40.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after buying an additional 64 shares during the last quarter. Institutional investors own 85.96% of the company's stock.

Masimo Stock Performance

Shares of NASDAQ:MASI traded up $0.47 during trading on Friday, hitting $152.15. 457,368 shares of the company were exchanged, compared to its average volume of 659,539. Masimo Co. has a 52-week low of $101.61 and a 52-week high of $194.88. The stock has a 50 day moving average of $168.04 and a 200 day moving average of $165.13. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The company has a market cap of $8.22 billion, a PE ratio of 104.93 and a beta of 1.28.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business had revenue of $600.70 million for the quarter, compared to analysts' expectations of $593.35 million. As a group, equities research analysts predict that Masimo Co. will post 4.1 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a research report on Thursday, April 10th. Wells Fargo & Company upped their price objective on Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Piper Sandler raised their target price on Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Finally, Raymond James upped their price target on Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a research report on Friday, December 27th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $194.80.

Insiders Place Their Bets

In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of the firm's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the sale, the director now owns 16,581 shares of the company's stock, valued at $2,754,601.53. This trade represents a 11.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Bilal Muhsin sold 30,000 shares of Masimo stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the sale, the chief operating officer now owns 24,172 shares of the company's stock, valued at approximately $4,048,568.28. This trade represents a 55.38 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 16.90% of the company's stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.